—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Protagonist Therapeutics Inc (PTGX) — chart, structure and Closelooknet read

The Closelooknet read

Protagonist Therapeutics is a clinical-stage biotechnology company that designs peptide-based drugs meant to work like larger biologic molecules but taken as oral or injectable treatments. Its lead programmes include a treatment for the blood disorder polycythemia vera and an oral therapy for plaque psoriasis, alongside earlier work in obesity and skin and lung disease.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for PTGX, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 45/100 · S&P 500 fund at 49, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-03
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 76th percentile of the window, -20.6% over 20 sessions. Factor regime → 2026-11-02
  • Sector × region Health care in US: +2.7% week · +9.9% month · +12.5% quarter · +24.7% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-11-03
  • Sovereign pressure Index -1.63 · down 2.22 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-02
How it trades on rate days beta 0.72 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How PTGX has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.72 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Protagonist Therapeutics Inc moved 0.72% on average · correlation 0.17 · higher than 67% of US names
  • Beta, last 3 months −0.15 less rate-sensitive lately than over the year
  • On the 10 worst bond days −1.70% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −0.98% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against PTGX on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Protagonist Therapeutics Inc

PTGX in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Protagonist Therapeutics is a clinical-stage biotechnology company that designs peptide-based drugs meant to work like larger biologic molecules but taken as oral or injectable treatments. Its lead programmes include a treatment for the blood disorder polycythemia vera and an oral therapy for plaque psoriasis, alongside earlier work in obesity and skin and lung disease. It is based in Newark, California, and has no approved product generating sales yet.
Where it sits in the stack
Protagonist carries no seat in our index and sits outside the semiconductor build-out entirely; it belongs to the clinical-stage biotechnology sleeve of the diary's healthcare coverage, where value depends on trial results rather than shipped volume.
Who it is priced against
There is no peer group set for this name in our coverage; the comparison an investor would draw is with other clinical-stage biotech companies developing peptide or hormone-mimetic drugs for rare and immune conditions, a group that includes larger developers such as Amgen when a partnership or licensing deal is in view.
Why Closelooknet tracks it
It holds no index seat and is not quoted in the editions. It carries a Closelooknet score, but only one module has been scored so far, so the read is still being built.
What the diary watches
Whether trial results for its lead programmes, particularly the rare blood disorder treatment in late-stage testing, move the shares more than the broader index moves on any given day.

Protagonist Therapeutics Inc (PTGX) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 60/100 composite (momentum 81, quality 61, valuation 10) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 2 analyst actions on the wire · latest: price target by BMO Capital, 2026-09-01

The Street on this name

Analyst actions and the latest print for PTGX from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target BMO Capital — target 190 from 178 Target raised to $190 from $178 (+28.6% to spot) 2026-09-01
  • Price target H.C. Wainwright — target 170 from 167 Target raised to $170 from $167 (+17.6% to spot) 2026-08-31

2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months

Dividends and capital return

What PTGX pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count −2.3% in FY2025 46 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-04

Quick answers

What is Protagonist Therapeutics Inc (PTGX)?

Protagonist Therapeutics Inc trades as PTGX on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-04.

Is PTGX in a Closelooknet index?

Not currently — Protagonist Therapeutics Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-04.

What is Protagonist Therapeutics Inc's Closelooknet composite score?

60 out of 100, with momentum 81, quality 61 and valuation 10 sub-scores, as of 2026-11-04. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does PTGX trade against its moving averages?

Protagonist Therapeutics Inc trades 1.5% below its 50-day and 19.7% above its 200-day moving average (0.5% above its 20-day). As of 2026-11-03 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Protagonist Therapeutics Inc compare with its peers?

Against its peer group (Biotechnology · US), Protagonist Therapeutics Inc (PTGX) sits 12.8% below its 52-week high, 1.5% below its 50-day average; Halozyme Therapeutics Inc (HALO) is 4.0% below, BeOne Medicines AG (ONC) is 8.7% below, argenx NV ADR (ARGX) is 16.0% below, as of 2026-11-03. Put any of them next to PTGX in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Protagonist Therapeutics Inc trade when bond yields rise?

Over the past year Protagonist Therapeutics Inc had a beta of 0.72 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 67% of US names. On the 10 sessions in which long bonds fell most it moved −1.70% on average, against −0.74% for the S&P 500. As of 2026-11-03; The "How it trades on rate days" block on this page carries the lines.

What does Protagonist Therapeutics Inc do?

Protagonist Therapeutics is a clinical-stage biotechnology company that designs peptide-based drugs meant to work like larger biologic molecules but taken as oral or injectable treatments. Its lead programmes include a treatment for the blood disorder polycythemia vera and an oral therapy for plaque psoriasis, alongside earlier work in obesity and skin and lung disease. It is based in Newark, California, and has no approved product generating sales yet. There is no peer group set for this name in our coverage; the comparison an investor would draw is with other clinical-stage biotech companies developing peptide or hormone-mimetic drugs for rare and immune conditions, a group that includes larger developers such as Amgen when a partnership or licensing deal is in view. (Company snapshot of 2026-09-17.)

Where does Protagonist Therapeutics Inc sit in the AI build-out?

Protagonist carries no seat in our index and sits outside the semiconductor build-out entirely; it belongs to the clinical-stage biotechnology sleeve of the diary's healthcare coverage, where value depends on trial results rather than shipped volume. It holds no index seat and is not quoted in the editions. It carries a Closelooknet score, but only one module has been scored so far, so the read is still being built. (Company snapshot of 2026-09-17.)

Does Protagonist Therapeutics Inc pay a dividend?

No cash distribution shows in Protagonist Therapeutics Inc’s price series over the last three years. The share count fell 2.3% over the fiscal year. As of 2026-11-03; the "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Protagonist Therapeutics Inc recently?

The most recent analyst action on Protagonist Therapeutics Inc on the Closelooknet wire is a price target by BMO Capital on 2026-09-01 (target 190 from 178). 2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for PTGX, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.